Ticking the Boxes

In this episode, we welcome the lead author of “Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A phase 2, Randomized, Double-Blind, Placebo-Controlled Trial” Dr. Eric Morand of Monash University. The objective of this multicenter clinical trial in lupus (recently published in “Arthritis & Rheumatology”) was to assess the efficacy of deucravacitinib in a phase II trial in adult patients with active lupus. Dr. Morand’s methods, results and ultimate conclusions take center stage of our show today.